JP2013514974A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514974A5
JP2013514974A5 JP2012544727A JP2012544727A JP2013514974A5 JP 2013514974 A5 JP2013514974 A5 JP 2013514974A5 JP 2012544727 A JP2012544727 A JP 2012544727A JP 2012544727 A JP2012544727 A JP 2012544727A JP 2013514974 A5 JP2013514974 A5 JP 2013514974A5
Authority
JP
Japan
Prior art keywords
hydrogen
amino
compound
salt
bicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012544727A
Other languages
English (en)
Japanese (ja)
Other versions
JP5779190B2 (ja
JP2013514974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/060371 external-priority patent/WO2011084437A1/en
Publication of JP2013514974A publication Critical patent/JP2013514974A/ja
Publication of JP2013514974A5 publication Critical patent/JP2013514974A5/ja
Application granted granted Critical
Publication of JP5779190B2 publication Critical patent/JP5779190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012544727A 2009-12-21 2010-12-15 Mglu2アゴニスト Active JP5779190B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382290.6 2009-12-21
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
US61/305,239 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (3)

Publication Number Publication Date
JP2013514974A JP2013514974A (ja) 2013-05-02
JP2013514974A5 true JP2013514974A5 (cg-RX-API-DMAC7.html) 2014-01-23
JP5779190B2 JP5779190B2 (ja) 2015-09-16

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544727A Active JP5779190B2 (ja) 2009-12-21 2010-12-15 Mglu2アゴニスト

Country Status (35)

Country Link
US (1) US8318184B2 (cg-RX-API-DMAC7.html)
EP (1) EP2516406B1 (cg-RX-API-DMAC7.html)
JP (1) JP5779190B2 (cg-RX-API-DMAC7.html)
KR (1) KR101395356B1 (cg-RX-API-DMAC7.html)
CN (1) CN102695701B (cg-RX-API-DMAC7.html)
AR (1) AR079343A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010340039B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012017188B1 (cg-RX-API-DMAC7.html)
CA (1) CA2784667C (cg-RX-API-DMAC7.html)
CR (1) CR20120322A (cg-RX-API-DMAC7.html)
CY (1) CY1114880T1 (cg-RX-API-DMAC7.html)
DK (1) DK2516406T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000173A (cg-RX-API-DMAC7.html)
EA (1) EA020229B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011989A (cg-RX-API-DMAC7.html)
ES (1) ES2435651T3 (cg-RX-API-DMAC7.html)
HN (1) HN2012001160A (cg-RX-API-DMAC7.html)
HR (1) HRP20131052T1 (cg-RX-API-DMAC7.html)
IL (1) IL220011A (cg-RX-API-DMAC7.html)
JO (1) JO2978B1 (cg-RX-API-DMAC7.html)
MA (1) MA33824B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012007332A (cg-RX-API-DMAC7.html)
MY (1) MY160618A (cg-RX-API-DMAC7.html)
NZ (1) NZ600305A (cg-RX-API-DMAC7.html)
PE (1) PE20121688A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501253A1 (cg-RX-API-DMAC7.html)
PL (1) PL2516406T3 (cg-RX-API-DMAC7.html)
PT (1) PT2516406E (cg-RX-API-DMAC7.html)
RS (1) RS53063B (cg-RX-API-DMAC7.html)
SG (1) SG181836A1 (cg-RX-API-DMAC7.html)
SI (1) SI2516406T1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000281A1 (cg-RX-API-DMAC7.html)
TW (1) TWI477490B (cg-RX-API-DMAC7.html)
UA (1) UA107684C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011084437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2540728T1 (sl) 2010-02-17 2019-06-28 Takeda Pharmaceutical Company Limited Heterociklična spojina
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
US9056844B2 (en) * 2010-11-18 2015-06-16 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
ES2587204T3 (es) * 2011-06-17 2016-10-21 Eli Lilly And Company Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas del receptor mGlu2
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
HRP20191646T1 (hr) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
CN109999033B (zh) * 2014-01-21 2022-12-23 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US7038077B2 (en) * 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids
CN1267407C (zh) * 2001-01-11 2006-08-02 伊莱利利公司 兴奋性氨基酸前体药物
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
JP4342437B2 (ja) * 2002-06-11 2009-10-14 イーライ リリー アンド カンパニー 興奮性アミノ酸のプロドラッグ
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
US9056844B2 (en) * 2010-11-18 2015-06-16 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists

Similar Documents

Publication Publication Date Title
JP2013514974A5 (cg-RX-API-DMAC7.html)
JP2013514980A5 (cg-RX-API-DMAC7.html)
JP2013530958A5 (cg-RX-API-DMAC7.html)
JP2014506907A5 (cg-RX-API-DMAC7.html)
MX2013009709A (es) Derivados de heteroarilo como moduladores de nachr alfa 7.
JP2014526549A5 (cg-RX-API-DMAC7.html)
JP2011528658A5 (cg-RX-API-DMAC7.html)
JP2015537020A5 (cg-RX-API-DMAC7.html)
JP2013542261A5 (cg-RX-API-DMAC7.html)
JP2012519182A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2014507455A5 (cg-RX-API-DMAC7.html)
JP2010529118A5 (cg-RX-API-DMAC7.html)
RU2009133262A (ru) Нападизилатная соль антагониста мускаринового мз-рецептора
JP2014515013A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
JP2010500293A5 (cg-RX-API-DMAC7.html)
JP2016510323A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
HRP20131052T1 (hr) Agonisti mglu2
JP2012507535A5 (cg-RX-API-DMAC7.html)
MX2013011290A (es) Derivados de pirrol como moduladores de los receptores de acetilcolina nicotinicos para su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer y la enfermedad de parkinson.
NZ596820A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
JP2016529315A5 (cg-RX-API-DMAC7.html)
MX2012003720A (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.